JP2020518651A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020518651A5 JP2020518651A5 JP2019561277A JP2019561277A JP2020518651A5 JP 2020518651 A5 JP2020518651 A5 JP 2020518651A5 JP 2019561277 A JP2019561277 A JP 2019561277A JP 2019561277 A JP2019561277 A JP 2019561277A JP 2020518651 A5 JP2020518651 A5 JP 2020518651A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- pharmaceutical composition
- abu
- fine particles
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Withdrawn
Links
- 239000010419 fine particle Substances 0.000 claims 22
- 239000008194 pharmaceutical composition Substances 0.000 claims 19
- 108090000765 processed proteins & peptides Proteins 0.000 claims 16
- 230000001772 anti-angiogenic effect Effects 0.000 claims 7
- 150000001413 amino acids Chemical class 0.000 claims 6
- 229920001606 poly(lactic acid-co-glycolic acid) Polymers 0.000 claims 6
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 claims 4
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 claims 4
- 208000002780 macular degeneration Diseases 0.000 claims 4
- 206010064930 age-related macular degeneration Diseases 0.000 claims 3
- 238000002560 therapeutic procedure Methods 0.000 claims 3
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 claims 2
- 206010012689 Diabetic retinopathy Diseases 0.000 claims 2
- 229920006022 Poly(L-lactide-co-glycolide)-b-poly(ethylene glycol) Polymers 0.000 claims 2
- 125000003275 alpha amino acid group Chemical group 0.000 claims 2
- 235000014655 lactic acid Nutrition 0.000 claims 2
- 239000004310 lactic acid Substances 0.000 claims 2
- 208000004644 retinal vein occlusion Diseases 0.000 claims 2
- 102000004266 Collagen Type IV Human genes 0.000 claims 1
- 108010042086 Collagen Type IV Proteins 0.000 claims 1
- 206010012688 Diabetic retinal oedema Diseases 0.000 claims 1
- 208000001344 Macular Edema Diseases 0.000 claims 1
- 206010025415 Macular oedema Diseases 0.000 claims 1
- 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims 1
- 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims 1
- 208000000208 Wet Macular Degeneration Diseases 0.000 claims 1
- 201000011190 diabetic macular edema Diseases 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000000835 fiber Substances 0.000 claims 1
- 201000010230 macular retinal edema Diseases 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 229920000642 polymer Polymers 0.000 claims 1
- 102000004196 processed proteins & peptides Human genes 0.000 claims 1
- 238000011282 treatment Methods 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762502913P | 2017-05-08 | 2017-05-08 | |
| US62/502,913 | 2017-05-08 | ||
| PCT/US2018/031663 WO2018208829A1 (en) | 2017-05-08 | 2018-05-08 | Biodegradable microparticles for sustained delivery of anti-angiogenic peptide |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2020518651A JP2020518651A (ja) | 2020-06-25 |
| JP2020518651A5 true JP2020518651A5 (enExample) | 2021-07-26 |
Family
ID=64104968
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019561277A Withdrawn JP2020518651A (ja) | 2017-05-08 | 2018-05-08 | 抗血管新生ペプチドの持続送達のための生分解性微粒子 |
Country Status (8)
| Country | Link |
|---|---|
| US (1) | US20200179285A1 (enExample) |
| EP (1) | EP3621597A4 (enExample) |
| JP (1) | JP2020518651A (enExample) |
| KR (1) | KR20200003859A (enExample) |
| CN (1) | CN111315364A (enExample) |
| AU (1) | AU2018266690A1 (enExample) |
| CA (1) | CA3063140A1 (enExample) |
| WO (1) | WO2018208829A1 (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NZ771201A (en) | 2017-04-06 | 2025-01-31 | Sustain Holdings Llc | Collagen Peptide-Based Medicament Compositions And Devices And Methods Of Production And Use Thereof |
| EP3661536A4 (en) | 2017-08-03 | 2021-07-21 | Asclepix Therapeutics, Inc. | PROCESSES FOR IDENTIFYING AND PREPARING PHARMACEUTICAL AGENTS TO ACTIVATE THE TIE2 RECEPTOR |
| KR20210146352A (ko) * | 2019-03-26 | 2021-12-03 | 아스클리픽스 테라퓨틱스, 인크. | 안구 질환 치료용 조성물 및 방법 |
| PT3958889T (pt) | 2019-04-22 | 2025-04-10 | Sustain Holdings Llc | Composições de péptidos miméticos de colagénio para o tratamento de uma doença ou perturbação ocular so segmento posterior que envolve a retina, os vasos sanguíneos da retina, os nervos retinianos ou o nervo ótico |
| IT202100023357A1 (it) | 2021-09-09 | 2023-03-09 | Cheirontech S R L | Peptidi con attività anti-angiogenica |
| CN117126233A (zh) * | 2022-05-20 | 2023-11-28 | 杭州禾泰健宇生物科技有限公司 | 一种类肽化合物及其应用 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9717694B2 (en) * | 2009-05-15 | 2017-08-01 | The Johns Hopkins University | Peptide/particle delivery systems |
| US10314917B2 (en) * | 2013-03-15 | 2019-06-11 | The Brigham And Women's Hospital, Inc. | Targeted polymeric inflammation-resolving nanoparticles |
| DK3003343T3 (da) * | 2013-06-07 | 2020-02-03 | Univ Johns Hopkins | Biomimetisk peptid og bionedbrydelig leveringsplatform til behandling af angiogenese- og lymfangiogeneseafhængige sygdomme |
| JP2019535651A (ja) * | 2016-10-04 | 2019-12-12 | アスクレピクス セラピューティクス インコーポレイテッド | Ｔｉｅ２シグナル伝達を活性化するための化合物及び方法 |
-
2018
- 2018-05-08 WO PCT/US2018/031663 patent/WO2018208829A1/en not_active Ceased
- 2018-05-08 KR KR1020197035367A patent/KR20200003859A/ko not_active Ceased
- 2018-05-08 CA CA3063140A patent/CA3063140A1/en not_active Abandoned
- 2018-05-08 AU AU2018266690A patent/AU2018266690A1/en not_active Abandoned
- 2018-05-08 CN CN201880039876.3A patent/CN111315364A/zh active Pending
- 2018-05-08 EP EP18797771.5A patent/EP3621597A4/en not_active Withdrawn
- 2018-05-08 JP JP2019561277A patent/JP2020518651A/ja not_active Withdrawn
- 2018-05-08 US US16/612,124 patent/US20200179285A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2020518651A5 (enExample) | ||
| Ward et al. | Neuroprotection of retinal ganglion cells in DBA/2J mice with GDNF-loaded biodegradable microspheres | |
| JP6700348B2 (ja) | 持続型薬物送達インプラント | |
| JP2018500394A5 (enExample) | ||
| JP2008528446A5 (enExample) | ||
| ES2782111T3 (es) | Micropartículas cargadas con ciclosporina de liberación sostenida | |
| US9044436B2 (en) | Compositions and methods for the treatment of angiogenesis-related eye diseases | |
| JP2019535651A5 (enExample) | ||
| JP2020518651A (ja) | 抗血管新生ペプチドの持続送達のための生分解性微粒子 | |
| CA2891365A1 (en) | Composition for immediate and extended release | |
| CN1638734A (zh) | 微粒结膜下给药的药物释放系统 | |
| US20150306170A1 (en) | Composition for immediate and extended release | |
| CN111032022B (zh) | 用于治疗癌症和眼疾病的白蛋白纳米粒 | |
| EP3810087A1 (en) | Bioresponsive hydrogel matrixes and methods of use | |
| JP2017523974A5 (enExample) | ||
| CN114632065A (zh) | 一种冻干制剂及其制备方法和应用 | |
| CN115190795A (zh) | 聚乙二醇化尿酸酶的制剂和剂量 | |
| RU2476235C2 (ru) | Композиции на основе биосовместимых микрочастиц альгиновой кислоты, предназначенные для регулируемого высвобождения активных ингредиентов при внутривенном введении | |
| JPWO2021195163A5 (enExample) | ||
| KR101732609B1 (ko) | 생리활성물질의 순차적 방출제어를 위한 고분자 혼합 제제 | |
| TWI660740B (zh) | 水膠組合物及包含其之藥物傳輸系統 | |
| CN107970204B (zh) | 水凝胶组合物及包含其的药物递送系统 | |
| Karagoz et al. | PRODUCING AFLIBERCEPT LOADED POLY (LACTIC co GLYCOLIC ACID)[PLGA] NANOPARTICLES AS A NEW OCULAR DRUG DELIVERY SYSTEM AND ITS CHALLENGES | |
| CN120267619A (zh) | 一种奥氮平长效缓释微球制剂及其制备方法与应用 | |
| CN104906587B (zh) | 一种膦甲酸钠眼玻璃体腔内缓释药物 |